


Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

6

Complete if Known

Application Number 09/614,389

Filing Date 7/12/2000

First Named Inventor RASOR

Group Art Unit

Examiner Name

Attorney Docket Number CAPR 1010

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ANTON F, EUCHNER I, HANDWERKER HO. Psychophysical examination of pain induced by defined CO ₂ pulses applied to the nasal mucosa. Pain 49:53-60, 1992	
		CHA EJ, SEDLOCK D, YAMASHIRO SM. Changes in lung volume and breathing pattern during exercise and CO ₂ inhalation in humans. J Appl Physiol 62(4):1544-50, Apr 1987	
		DEXTER SL. Rebreathing aborts migraine attacks. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):312	
		DIAMOND S, DALESSIO DJ, course directors. The 13th Annual Practicing Physician's Approach to the Difficult Headache Patient. Rancho Mirage, CA. February 15-19, 2000	
		ECHARRI RM, RIVERA T, MATE MA, COBETA I. [Sudden deafness: efficacy of a therapeutic protocol]. [Article in Spanish] Acta Otorrinolaringol Esp 51(6):490-4 Aug-Sep 2000	
		FAISY C, DIEHL JL, GUEROT E, REZGUI N, LABROUSSE J. [Use of the helium-oxygen mixture in pneumology practice]. [Article in French]. Rev Mal Respir 1999 Dec;16(6):1063-73	
		FIEMONTE G, PIERELLI F, PAURI F, COSENTINO FII, SOCCORSI R, GIACOMINI P. Cerebrovascular CO ₂ reactivity in migraine with aura and without aura. A transcranial Doppler study. Acta Neurol Scand 92(2):166-9, Aug 1995	
		FISHER HK, HANSEN TA. Site of action of inhaled 6 percent carbon dioxide in the lungs of asthmatic subjects before and after exercise. Am Rev Respir Dis 114(5):861-870, 1976.	
		FISHER HK, HOLTON P, BUXTON R ST J, NADEL JA. Resistance to breathing during exercise-induced asthma attacks. Amer Rev Resp Dis 101:885-896, 1970	
		GILLMAN MA, LICHTIGFELD FJ. Placebo and analgesic nitrous oxide for treatment of the alcohol withdrawal state. Br J Psychiatry 159:672-5, Nov 1991	
		GLOVSKY MM. Upper airways involvement in bronchial asthma. Cur Opin in Pulm Med 4:54-58, 1998	

Examiner Signature

Date

Considered

22 SEP 17 2001

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


RECEIVED
SEP 17 2001
TECHNOLOGY
DIVISION 3700

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	09/614,389
Filing Date	7/12/2000
First Named Inventor	Rasor
Group Art Unit	
Examiner Name	
Attorney Docket Number	CAPR 1010

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GROSSER, K.; OELKERS, R.; HUMMEL, T.; GEISLINGER, G.; BRUNE, K.; KOBAL, G.; L. TSCH, J. Olfactory and trigeminal event-related potentials in migraine. Cephalalgia 2000 Sep;20:621-31	
		GROSSHANS A, GENSCH H. [CO ₂ gas injection – indications and results]. Z Gesamte Inn Med 42(23):667-70, 1987	✓
		GUYTON AC, HALL JE. Textbook of Medical Physiology. Ninth Edition, WB Saunders, Philadelphia, 1996, pp. 101, 203-04, 206-07, 454, 487, 515, 520-23, 527-30, 541-44, 572-73, 617-19, 694	
		HOLLMAN G, SHEN G, ZENG L, YNGSDAL-KRENZ R, PERLOFF W, ZIMMERMAN J, STRAUSS R. Helium-oxygen improves Clinical Asthma Scores in children with acute bronchiolitis. Crit Care Med 26(10):1731-6, Oct 1998	
		JOLLIET P, TASSAUX D, THOURET JM, CHEVROLET JC. Beneficial effects of helium-oxygen versus air-oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease. Crit Care Med 27(11):2422-9, Nov 1999	
		RODARTE JR, HYATT RE. Effect of acute exposure to CO ₂ on lung mechanics in normal man. Resp Physiol 17:135-145, 1973	
		SAQUETON CB, MILLER RB, PORTER VA, MILLA CE, CORNFELD DN. NO causes perinatal pulmonary vasodilation through K ⁺ -channel activation and intracellular Ca ²⁺ release. Am J Physiol 276(6 Pt 1):L925-L932, Jun 1999	
		SCHAEFFER EM, POHLMAN A, MORGAN S, HALL JB. Oxygenation in status asthmaticus improves during ventilation with helium-oxygen. Crit Care Med 27(12):2666-70, Dec 1999	
		SCHUTTAUF F, COBET U, KLEMENZ A, KRAUSE A. [Duplex ultrasound examinations of retinal circulation after inhalation of various mixed respiratory gases.] Ophthalmologie 95(4):225-8, Apr 1998	
		SINGH V, WISNIEWSKI A, BRITTON J, TATTERSFIELD A. Effect of yoga breathing exercises (pranayama) on airway reactivity in subjects with asthma. Lancet 335:1381-3, 1990	
		STERLING GM, HOLST PE, NADEL JA. Effect of CO ₂ and pH on bronchoconstriction caused by serotonin vs. acetylcholine. J. Appl. Physiol. 32(1):39-43, Jan 1972	

RECEIVED
SEP 18 2001
TECHNOLOGY CENTER 3700

Examiner Signature		Date Considered	20/1/01
-----------------------	--	--------------------	---------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐ +

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

6

Complete if Known

Application Number	09/664,389
Filing Date	07/12/2000
First Named Inventor	Rasor
Group Art Unit	
Examiner Name	
Attorney Docket Number	CAPR 1010

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JOZEFOWICZ RF. Neurologic manifestations of pulmonary disease. Neurologic Clinics 7(3):605-616, 1989	
		LOEVENHART AS, LORENZ WF, WATERS RM. Cerebral stimulation. JAMA 92(11):880-883, 1929	
		LOH E, LANKFORD EB, POLIDORI DJ, DOERING-LUBIT EB, HANSON CW, ACKER MA. Cardiovascular effects of inhaled nitric oxide in a canine model of cardiomyopathy. Ann Thorac Surg 67(5):1380-5, May 1999	
		MARCUSSEN RM, WOLFF HG. Studies on headache: 1. Effects of carbon dioxide-oxygen mixtures given during the pre-headache phase of the migraine attack. 2. Further analysis of pain mechanisms in headache. Arch Neurol Psychiatry 63:42-61, 1950	
		MEDUNA LJ ed, Carbon Dioxide Therapy A Neurophysiological Treatment of Nervous Disorders. Second Edition, LJ Charles C. Thomas publisher, Springfield, IL, 1958	
		MEDUNA LJ. Pharmacodynamic treatment of psychoneuroses (a preliminary report). Dis Nerv System 8(2), 1947	
		NATIONAL HEADACHE FOUNDATION. A Patient's Guide to Migraine Prevention & Treatment. Chicago, IL, Aug 1996	
		NAVARRA P, DELLO RUSSO C, MANCUSO C, PREZIOSI P, GROSSMAN A. Gaseous neuromodulators in the control of neuroendocrine stress axis. Ann N Y Acad Sci 2000;917:638-46	
		NIELSEN TM, PEDERSEN OF. The effect of CO ₂ on peripheral airways. Acta Physiol Scand 98(2):192-9, Oct 1976	
		PAGANO D, TOWNEND JN, HORTON R, SMITH C, CLUTTON-BROCK T, BONSER RS. A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Eur J Cardiothorac Surg 10(12):1120-6, 1996	
		REAM RS, HAUVER JF, LYNCH RE, KOUNTZMAN B, GALE GB, MINK RB. Low dose inhaled nitric oxide improves the oxygenation and ventilation of infants and children with acute, hypoxemic respiratory failure. Crit Care Med 27(5):989-96, May 1999	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	09/614,389
Filing Date	7/12/2000
First Named Inventor	Rasor
Group Art Unit	
Examiner Name	
Attorney Docket Number	CAPP1010

(use as many sheets as necessary)

Sheet	4	of	6
-------	---	----	---

[illegible]

**Examiner
Signature**

Date
Considered

02 11 2022

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	09/614,389
Filing Date	7/12/2000
First Named Inventor	Rasor
Group Art Unit	
Examiner Name	
Attorney Docket Number	CARR 1010

(use as many sheets as necessary)

Sheet	5	of	6	Attorney Docket Number	CARR 1010
-------	---	----	---	------------------------	-----------

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patente or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		1,288,850		Easly	12/24/1918	
		1,449,047		Johnson	03/20/1923	
		2,651,303		Johnson, et al.	09/08/1953	
		2,860,634		Duncan, et al.	11/18/1958	
		3,513,843		Exler	05/26/1970	
		3,776,227		Pitesky, et al.	12/04/1973	
		3,870,072		Lindmann	03/11/1975	
		3,934,585		Maurice	01/27/1976	
		4,067,499		Cohen	01/10/1978	
		4,137,914		Wetterlin	02/06/1979	
		4,554,916		Watt	11/26/1985	
		5,262,180		Orlando, et al.	11/16/1993	
		5,431,155		Marelli	07/11/1995	
		5,485,827		Zapol	01/23/1996	
		5,570,683		Zapol	11/05/1996	
		5,807,357		Kang	09/15/1998	
		5,938,590		Elliot	08/17/1999	
			5,941,241		Weinstein, et al.	08/24/1999
		5,983,891		Fukunaga	11/16/1999	
		5,993,428		Hardee	11/30/1999	

[illegible]

RECEIVED
SEP 18 2001
TECHNOLOGY CENTER

**Examiner
Signature**

Date

Considered

22 Nov 02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**


+



+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Application Number	09/614,389
Filing Date	7/12/2000
First Named Inventor	Rasor
Group Art Unit	
Examiner Name	

(use as many sheets as necessary)

Sheet	6	of	6	Attorney Docket Number	CAPR 1010
-------	---	----	---	------------------------	-----------

[illegible][illegible]

Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**